West Pharmaceutical(WST) Prnewswire·2025-05-20 09:45Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand visibility and attributed challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - Consequently, the positive statements made by the defendants about the company's business, operations, and prospects were materially false, misleading, or lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].